Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: Are we there yet?

Primary Care Respiratory Journal

Volumn 20, Issue 4, 2011, Pages 360-367

  Aabenhus, Rune ^a   Jensen, Jens Ulrik Stæhr ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

Acute respiratory infections; Biomarkers; Diagnostic tests; Primary care; Procalcitonin

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN;

ANTIBIOTIC THERAPY; CLINICAL ASSESSMENT; DISEASE MARKER; DRUG INDICATION; GOLD STANDARD; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; LABORATORY TEST; OBSERVATIONAL STUDY; POINT OF CARE TESTING; PRIMARY MEDICAL CARE; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE VALUE; RESPIRATORY TRACT INFECTION; REVIEW;

EID: 85027923870     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2011.00064     Document Type: Review

References (55)

1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48(1):1-12. http://dx.doi.org/10.1086/595011
2. Goossens H, Ferech M, Vander SR, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365(9459):579-87.
3. Sande-Bruinsma N, Grundmann H, Verloo D, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008;14(11):1722-30. http://dx.doi.org/10.3201/eid1411.070467
4. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997;278(17):1440-5. http://dx.doi.org/10.1001/jama.278.17.1440
5. Hoare Z, Lim WS. Pneumonia: update on diagnosis and management. BMJ 2006;332(7549):1077-9. http://dx.doi.org/10.1136/bmj.332.7549.1077
6. Wipf JE, Lipsky BA, Hirschmann JV, et al. Diagnosing pneumonia by physical examination: relevant or relic? Arch Intern Med 1999;159(10):1082-7. http://dx.doi.org/10.1001/archinte.159.10.1082.
7. Matthys J, De MM, van Driel ML, De SA. Differences among international pharyngitis guidelines: not just academic. Ann Fam Med 2007;5(5):436-43. http://dx.doi.org/10.1370/afm.741.
8. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev 2005;(4):CD003539.
9. Fakih MG, Berschback J, Juzych NS, Massanari M. Compliance of resident and staff physicians with IDSA guidelines for the diagnosis and treatment of streptococcal pharyngitis. Infect Dis Clin Pract 2006;14:84-8. http://dx.doi.org/10.1097/01.idc.0000198462.55744.f8
10. Little P. Penicillin for acute sore throat in children: randomised, double blind trial. Commentary: More valid criteria may be needed. BMJ 2003;327(7427):1327-8. http://dx.doi.org/10.1136/bmj.327.7427.1327
11. Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis 2001;33(6):757-62. http://dx.doi.org/10.1086/322627
12. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008;47(6):735-43. http://dx.doi.org/10.1086/591126
13. Butler CC, Simpson S, Wood F. General practitioners' perceptions of introducing near-patient testing for common infections into routine primary care: a qualitative study. Scand J Prim Health Care 2008;26(1):17-21. http://dx.doi.org/10.1080/02813430701726285
14. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008;36(3):941-52. http://dx.doi.org/10.1097/CCM.0B013E318165BABB
15. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302(10):1059-66. http://dx.doi.org/10.1001/jama.2009.1297
16. Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008;168(18):2000-07. http://dx.doi.org/10.1001/archinte.168.18.2000
17. Christ-Crain M, Schuetz P, Muller B. Biomarkers in the management of pneumonia. Expert Rev Respir Med 2008;2(5):565-72. http://dx.doi.org/10.1586/17476348.2.5.565
18. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004;89(4):1512-25. http://dx.doi.org/10.1210/jc.2002-021444
19. Snider RH, Jr., Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med 1997;45(9):552-60.
20. Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Muller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 2004;32(8):1715-21. http://dx.doi.org/10.1097/01.CCM.0000134404.63292.71
21. Linscheid P, Seboek D, Nylen ES, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology 2003;144(12):5578-84. http://dx.doi.org/10.1210/en.2003-0854
22. Christ-Crain M, Muller B. Procalcitonin in bacterial infections-hype, hope, more or less? Swiss Med Wkly 2005;135(31-32):451-60.
23. Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994;79(6):1605-08. http://dx.doi.org/10.1210/jc.79.6.1605
24. Meisner M, Schmidt J, Huttner H, Tschaikowsky K. The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med 2000;26(Suppl 2):S212-16.
25. Gaini S, Koldkjaer OG, Moller HJ, Pedersen C, Pedersen SS. A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study. Crit Care 2007;11(4):R76. http://dx.doi.org/10.1186/cc5967
26. Daubin C, Parienti JJ, Fradin S, et al. Procalcitonin levels and bacterial aetiology among COPD patients admitted to the ICU with severe pneumonia: a prospective cohort study. BMC Infect Dis 2009;9:157. http://dx.doi.org/10.1186/1471-2334-9-157
27. Moulin F, Raymond J, Lorrot M, et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 2001;84(4):332-6. http://dx.doi.org/10.1136/adc.84.4.332
28. Holm A, Pedersen SS, Nexoe J, et al. Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. Br J Gen Pract 2007;57(540):555-60.
29. Ingram PR, Inglis T, Moxon D, Speers D. Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection. Intensive Care Med 2010;36(3):528-32. http://dx.doi.org/10.1007/s00134-009-1746-3
30. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006;34(10):2596-602. http://dx.doi.org/10.1097/ 01.CCM.0000239116.01855.61
31. Nylen ES, Whang KT, Snider RH, Jr., Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998;26(6):1001-06. http://dx.doi.org/10.1097/00003246-199806000-00015
32. Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections-hope for hype? Swiss Med Wkly 2009;139(23-24):318-26.
33. Kruger S, Ewig S, Papassotiriou J, et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009;10:65. http://dx.doi.org/10.1186/1465-9921-10-65
34. Korczowski B, Malek U, Kowalczyk JR, Rybak A, Zinkiewicz A, Chmielewska A. [Two diagnostic assays for serum procalcitonin measurement in clinical practice]. Przegl Lek 2003;60(5):345-8.
35. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010;14(1):203. http://dx.doi.org/10.1186/cc8155
36. Steinbach G, Rau B, Debard AL, et al. Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor System. Clin ChemLab Med 2004;42(4):440-9. http://dx.doi.org/10.1515/CCLM.2004.077
37. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010;8(5):575-87. http://dx.doi.org/10.1586/eri.10.25
38. Burkhardt O, Ewig S, Haagen U, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 2010;36(3):601-07.
39. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26(6):1138-80. http://dx.doi.org/10.1183/09031936.05.00055705.
40. Melbye H, Dale K. Interobserver variability in the radiographic diagnosis of adult outpatient pneumonia. Acta Radiol 1992;33(1):79-81.
41. Wilkins TR, Wilkins RL. Clinical and radiographic evidence of pneumonia. Radiol Technol 2005;77(2):106-10.
42. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359(22):2355-65. http://dx.doi.org/10.1056/NEJMra0800353
43. Dinant GJ, Buntinx FF, Butler CC. The necessary shift from diagnostic to prognostic research. BMC Fam Pract 2007;8:53. http://dx.doi.org/10.1186/1471-2296-8-53
44. Korppi M, Remes S, Heiskanen-Kosma T. Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr Pulmonol 2003;35(1):56-61. http://dx.doi.org/10.1002/ppul.10201
45. Deis JN, Creech CB, Estrada CM, Abramo TJ. Procalcitonin as a marker of severe bacterial infection in children in the emergency department. Pediatr Emerg Care 2010;26(1):51-60. http://dx.doi.org/10.1097/PEC.0b013e3181c399df
46. Hopstaken RM, Coenen S, Butler CC. Treating patients not diagnoses: challenging assumptions underlying the investigation and management of LRTI in general practice. J Antimicrob Chemother 2005;56(5):941-3. http://dx.doi.org/10.1093/jac/dki330
47. Stanton N, Francis NA, Butler CC. Reducing uncertainty in managing respiratory tract infections in primary care. Br J Gen Pract 2010;60(581):e466-75. http://dx.doi.org/10.3399/bjgp10X544104
48. Cals JW, Butler CC, Hopstaken RM, Hood K, Dinant GJ. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ 2009;338:b1374. http://dx.doi.org/10.1136/bmj.b1374
49. Cals JW, Schot MJ, de Jong SA, Dinant GJ, Hopstaken RM. Point-of-care Creactive protein testing and antibiotic prescribing for respiratory tract infections: a randomized controlled trial. Ann Fam Med 2010;8(2):124-33. http://dx.doi.org/10.1370/afm.1090
50. Cals JW, Metlay JP. Procalcitonin-based guidelines and lower respiratory tract infections. JAMA 2010;303(5):418-20. http://dx.doi.org/10.1001/jama.2010.52
51. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008;52(1):48-58. http://dx.doi.org/10.1016/j.annemergmed.2008.01.003
52. Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008;31(2):349-55. http://dx.doi.org/10.1183/09031936.00054507
53. El MR, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PM. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008;63(5):415-22. http://dx.doi.org/10.1136/thx.2007.090613
54. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME. Short-versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 2008;68(13):1841-54. http://dx.doi.org/10.2165/00003495-200868130-00004
55. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010;340:c2096. http://dx.doi.org/10.1136/bmj.c2096.